Actively Recruiting
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
Led by Fox Chase Cancer Center · Updated on 2025-10-29
16
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims to answer are: * Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor? * Can ART help reduce the side effects that participants may experience during treatment? Participants will: * Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning. * Have a tumor biopsy, which involves taking a small sample of tissue from the cancer. * Receive 5 radiation treatments every other day over a 2-week period. * Provide blood samples before, during, and after your radiation treatment.
CONDITIONS
Official Title
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have confirmed pancreatic ductal adenocarcinoma by tissue or cell analysis.
- Patients must have locally advanced unresectable pancreatic cancer based on NCCN criteria.
- Patients reviewed by a multidisciplinary team including a pancreatic surgeon and determined unresectable.
- Patients may have started chemotherapy before radiation but must wait at least 2 weeks after last dose before starting ART.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
- Adequate bone marrow, liver, and kidney function as defined by specific lab values.
- Women of childbearing potential must not be pregnant and use effective birth control during and for 6 months after treatment.
- Patients must be 18 years or older.
- Participants must provide informed consent and be willing to comply with study procedures and follow-up.
You will not qualify if you...
- Presence of metastatic disease confirmed by imaging or cytology.
- Prior radiation therapy for pancreatic cancer.
- Prior chemoradiation to overlapping areas.
- Diagnosis of adenosquamous carcinoma of the pancreas.
- Chemotherapy within 2 weeks before study entry or not recovered from related side effects.
- Concurrent chemotherapy or biologic therapy not part of the study.
- History of ataxia telangiectasia or radiation hypersensitivity including certain genetic mutations.
- Serious active infections requiring IV antibiotics.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Actively Recruiting
Research Team
J
Joshua Meyer, MD
CONTACT
J
Jianli Hu, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here